TrialLeukemia & lymphoma2015

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).

Vicki A Morrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.